SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P.

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (81)3/19/1998 2:36:00 PM
From: scaram(o)ucheRead Replies (1) of 4974
 
Peter:

Love DM1. The question is, how do you make it work? Long ago I asked Mitch for data in mice, showing that DM1 was not immunogenic in mice when conjugated to a murine antibody. No response, but haven't checked lately to see if they've published the work.

Immunotoxin work is easy to do in mice. Trust me, you don't want to make it your business in humans.

They claim to have a patented procedure for humanization of monoclonals, one that circumvents MRC, GNE and PDLI patent positions. This procedure is central to their plans to use DM1. That is, they need to conjugate the toxin to something to deliver it to tumors, and they choose antibodies. Mitch's answer to my question in the IMGN thread, the answer regarding the nature of immunogenic peptides?? This should be a caution flag, and, what happens if "huC242" ain't "hu"?

I made notes in a lab notebook in 1987, indicating that ricin conjugates would not be useful in humans. Check the history of IMGN.

This said, I'm interested in the BCHE project and the subsidiary. And, I really do think that DM1 is quite fun.

Rick

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext